Literature DB >> 27696094

A Macrophage Migration Inhibitory Factor Polymorphism Is Associated with Autoimmune Hepatitis Severity in US and Japanese Patients.

David N Assis1, Hiroki Takahashi2, Lin Leng3, Mikio Zeniya2,4, James L Boyer3, Richard Bucala3.   

Abstract

BACKGROUND: The pathogenesis of autoimmune hepatitis (AIH) is incompletely understood. Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine implicated in the pathophysiology of multiple autoimmune diseases. We recently reported that MIF expression was increased in a US AIH cohort. MIF expression in non-Western AIH patients is unknown. A MIF-173 GC single nucleotide polymorphism in the MIF promoter (rs755622) is clinically associated with steroid resistance in several inflammatory disorders but has not been evaluated in AIH. AIM: To compare MIF polymorphisms and their relationship to clinical parameters in AIH patients from the USA and Japan.
METHODS: DNA and matched sera from AIH patients and healthy controls from Japan (N = 52) were compared to the US group. Serum concentrations of MIF and its circulating receptor CD74 were measured by ELISA. MIF-173 GC (rs755622) and MIF-794 CATT5-8 (rs5844572) polymorphisms were analyzed by standard methods. MIF genotypes were correlated with serum ALT and steroid requirements.
RESULTS: Serum MIF was increased in Japanese AIH patients versus local controls, in agreement with the US AIH patients. Within both AIH groups, ALT was higher in CC/GC versus GG patients. Further, the steroid requirement was higher in AIH patients with GC/CC genotypes from both groups. In the Japanese patient group, the GC/CC genotype also was associated with acute symptomatic presentation.
CONCLUSIONS: The MIF-173 CC/GC genotypes may be associated with both higher ALT and maintenance steroid requirements in AIH patients from the USA and Japan. This polymorphism could be a marker of disease severity in AIH patients.

Entities:  

Keywords:  Autoimmune hepatitis; Hepatitis; Liver disease; MIF; Macrophage migration inhibitory factor; Polymorphism

Mesh:

Substances:

Year:  2016        PMID: 27696094      PMCID: PMC5106299          DOI: 10.1007/s10620-016-4322-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  Genome-wide association study identifies variants associated with autoimmune hepatitis type 1.

Authors:  Ynto S de Boer; Nicole M F van Gerven; Antonie Zwiers; Bart J Verwer; Bart van Hoek; Karel J van Erpecum; Ulrich Beuers; Henk R van Buuren; Joost P H Drenth; Jannie W den Ouden; Robert C Verdonk; Ger H Koek; Johannes T Brouwer; Maureen M J Guichelaar; Jan M Vrolijk; Georg Kraal; Chris J J Mulder; Carin M J van Nieuwkerk; Janett Fischer; Thomas Berg; Felix Stickel; Christoph Sarrazin; Christoph Schramm; Ansgar W Lohse; Christina Weiler-Normann; Markus M Lerch; Matthias Nauck; Henry Völzke; Georg Homuth; Elisabeth Bloemena; Hein W Verspaget; Vinod Kumar; Alexandra Zhernakova; Cisca Wijmenga; Lude Franke; Gerd Bouma
Journal:  Gastroenterology       Date:  2014-04-23       Impact factor: 22.682

2.  Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission.

Authors:  Nicole M F van Gerven; Bart J Verwer; Birgit I Witte; Bart van Hoek; Minneke J Coenraad; Karel J van Erpecum; Ulrich Beuers; Henk R van Buuren; Rob A de Man; Joost P H Drenth; Jannie W den Ouden; Robert C Verdonk; Ger H Koek; Johannes T Brouwer; Maureen M J Guichelaar; Chris J J Mulder; Karin M J van Nieuwkerk; Gerd Bouma
Journal:  J Hepatol       Date:  2012-09-16       Impact factor: 25.083

Review 3.  Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflammatory disorders.

Authors:  Ivana Cvetkovic; Stanislava Stosic-Grujicic
Journal:  Int Immunopharmacol       Date:  2006-07-12       Impact factor: 4.932

4.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Authors:  F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

5.  Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance.

Authors:  H Murakami; S M Akbar; H Matsui; M Onji
Journal:  Eur J Clin Invest       Date:  2001-04       Impact factor: 4.686

6.  An essential regulatory role for macrophage migration inhibitory factor in T-cell activation.

Authors:  M Bacher; C N Metz; T Calandra; K Mayer; J Chesney; M Lohoff; D Gemsa; T Donnelly; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

7.  Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis.

Authors:  M A Llamas-Covarrubias; Y Valle; R Bucala; R E Navarro-Hernández; C A Palafox-Sánchez; J R Padilla-Gutiérrez; I Parra-Rojas; A G Bernard-Medina; Z Reyes-Castillo; J F Muñoz-Valle
Journal:  Cytokine       Date:  2013-02-09       Impact factor: 3.861

8.  Association of the macrophage migration inhibitory factor -173*C allele with childhood nephrotic syndrome.

Authors:  Marina Vivarelli; Leila Emma D'Urbano; Gilda Stringini; Gian Marco Ghiggeri; Gianluca Caridi; Rachelle Donn; Alberto Tozzi; Francesco Emma; Fabrizio De Benedetti
Journal:  Pediatr Nephrol       Date:  2008-01-29       Impact factor: 3.714

9.  MIF as a glucocorticoid-induced modulator of cytokine production.

Authors:  T Calandra; J Bernhagen; C N Metz; L A Spiegel; M Bacher; T Donnelly; A Cerami; R Bucala
Journal:  Nature       Date:  1995-09-07       Impact factor: 49.962

10.  A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still's disease.

Authors:  Fang-Fang Wang; Xin-Fang Huang; Nan Shen; Lin Leng; Richard Bucala; Shun-Le Chen; Liang-Jing Lu
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

View more
  10 in total

Review 1.  Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2018-04-18       Impact factor: 3.199

2.  A functional macrophage migration inhibitory factor promoter polymorphism is associated with reduced diffusing capacity.

Authors:  C Zhang; C Ramsey; A Berical; L Yu; L Leng; K A McGinnis; Y Song; H Michael; M C McCormack; H Allore; A Morris; K Crothers; R Bucala; P J Lee; M Sauler
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-12-06       Impact factor: 5.464

3.  Association of Macrophage Migration Inhibitory Factor Gene -173 G/C Polymorphism (rs755622) with Familial Mediterranean Fever in Children.

Authors:  Nursen Cakan; Resul Yılmaz; Erhan Karaaslan; Ömer Ateş
Journal:  J Pediatr Genet       Date:  2020-11-25

4.  CSF macrophage migration inhibitory factor levels did not predict steroid treatment response after optic neuritis in patients with multiple sclerosis.

Authors:  Marc Pawlitzki; Catherine M Sweeney-Reed; Sven G Meuth; Dirk Reinhold; Jens Neumann
Journal:  PLoS One       Date:  2018-11-26       Impact factor: 3.240

Review 5.  Novel Diagnostic and Therapeutic Strategies in Juvenile Autoimmune Hepatitis.

Authors:  Marco Sciveres; Silvia Nastasio; Giuseppe Maggiore
Journal:  Front Pediatr       Date:  2019-09-20       Impact factor: 3.418

6.  Polymorphism in Macrophage Migration Inhibitory Factor -173GC in Pediatric Patients with Autoimmune Hepatitis.

Authors:  Mona Abdel Latif Alsayed; Shymaa Mohsen Elbeah; Manal M El-Desoky; Shereen Magdy Elziny; Ahmed Megahed
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2020-01-08

Review 7.  Genetic risk factors for autoimmune hepatitis: implications for phenotypic heterogeneity and biomarkers for drug response.

Authors:  Takashi Higuchi; Shomi Oka; Hiroshi Furukawa; Shigeto Tohma; Hiroshi Yatsuhashi; Kiyoshi Migita
Journal:  Hum Genomics       Date:  2021-01-28       Impact factor: 4.639

8.  Leaky Gut Driven by Dysbiosis Augments Activation and Accumulation of Liver Macrophages via RIP3 Signaling Pathway in Autoimmune Hepatitis.

Authors:  Hongxia Zhang; Man Liu; Weilong Zhong; Yanping Zheng; Yanni Li; Liping Guo; Yujie Zhang; Ying Ran; Jingwen Zhao; Lu Zhou; Bangmao Wang
Journal:  Front Immunol       Date:  2021-03-25       Impact factor: 7.561

9.  Macrophage migration inhibitory factor in Nodding syndrome.

Authors:  Gil Benedek; Mahmoud Abed El Latif; Keren Miller; Mila Rivkin; Ally Ahmed Ramadhan Lasu; Lul P Riek; Richard Lako; Shimon Edvardson; Sagit Arbel-Alon; Eithan Galun; Mia Levite
Journal:  PLoS Negl Trop Dis       Date:  2021-10-18

10.  The Role of MIF-173G/C Gene Polymorphism in the Susceptibility of Autoimmune Diseases.

Authors:  Xiangrong Du; Ruixia Li; Shoujun Song; Lei Ma; Haibo Xue
Journal:  Mediators Inflamm       Date:  2020-04-28       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.